Innate Pharma SA said Tuesday that it would no longer explore its drug avdoralimab in Covid-19 after missing its Phase 2 targets but would continue to investigate its use in inflammation.
The oncology-focused biotech company said it didn't meet its primary endpoints in all three of its trial cohorts of Covid-19 patients with severe pneumonia.
The company said preclinical data that were observed didn't translate into clinical benefit over best supportive care.
Innate Pharma said these results don't affect the investigator-sponsored, Phase 2 trial of the treatment in the inflammatory disease bullous pemphigoid, for which it is enrolling patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.